Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Regulatory demands for cost-benefit studies.

W J Louis1

  • 1Department of Clinical Pharmacology, Austin Hospital, Heidelberg, Victoria, Australia.

American Heart Journal
|March 1, 1990
PubMed
Summary

Escalating drug costs in Australia, driven by new medications like ACE inhibitors, challenge affordability. A proposed two-tier Pharmaceutical Benefits Scheme aims to manage expenses but may impact access for some.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects.

British journal of clinical pharmacology·2015
Same author

A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension.

British journal of clinical pharmacology·2015
Same author

Age related changes in noradrenaline, noradrenaline turnover and adrenaline in brainstem nuclei of wistar kyoto and spontaneously hypertensive rats.

Neurochemistry international·2010
Same author

Comparison of ?-endorphin immunoreactivity in hypothalamic and brainstem nuclei of normotensive and age-matched hypertensive rat strains.

Neurochemistry international·2010
Same author

Role of the renin-angiotensin system in prostate cancer.

Molecular and cellular endocrinology·2008
Same author

Functional angiotensin II type 2 receptors inhibit growth factor signaling in LNCaP and PC3 prostate cancer cell lines.

The Prostate·2008

Area of Science:

  • Health Economics
  • Pharmacoeconomics
  • Australian Healthcare Policy

Background:

  • Significant increase in Australian drug costs observed in 1987-1988.
  • Introduction of angiotensin-converting enzyme (ACE) inhibitors contributed to rising pharmaceutical expenditure.
  • Concerns raised about the sustainability of high-cost new drugs for wealthy nations.

Purpose of the Study:

  • To examine the implications of escalating drug costs in Australia.
  • To evaluate the impact of revolutionary new drugs on healthcare budgets.
  • To propose modifications to the Australian Pharmaceutical Benefits Scheme.

Main Methods:

  • Analysis of drug cost trends and introduction of new drug classes.
  • Discussion of the Australian Pharmaceutical Benefits Scheme.
  • Proposal and evaluation of a two-tier system for drug listing and reimbursement.

Main Results:

  • New drugs, such as ACE inhibitors, significantly increased pharmaceutical costs.
  • A two-tier system is proposed to manage costs of new drugs.
  • Potential benefits include cost recovery and reduced overprescribing, but risks include limited access for lower socioeconomic groups.

Conclusions:

  • Affordability of high-cost new drugs is a critical issue for Australia.
  • A modified two-tier Pharmaceutical Benefits Scheme could balance cost management and access.
  • Further consideration of cost-benefit analyses within the total healthcare budget is essential.

Related Experiment Videos